Clinical Trials Logo

Raltitrexed clinical trials

View clinical trials related to Raltitrexed.

Filter by:
  • None
  • Page 1

NCT ID: NCT06427005 Recruiting - Fruquintinib Clinical Trials

Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

Based on the FRECO-2 study, Fruquintinib has become one of the standard third-line treatments for advanced colorectal cancer; however, its objective response rate (ORR) remains low. Our previous studies have shown that the combination of raltitrexed and S-1 -/+ bevacizumab is effective and provides a significant survival benefit in patients with metastatic colorectal cancer (mCRC) who are refractory to standard treatments. This study aims to evaluate the efficacy and safety of combining Fruquintinib with S-1 and raltitrexed in these patients.

NCT ID: NCT05426811 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Start date: July 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.

NCT ID: NCT04761185 Recruiting - Colorectal Cancer Clinical Trials

Raltitrexed in HIPEC

Start date: January 1, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the tolerance of patients with colorectal cancer to hyperthermic intraperitoneal chemotherapy with Raltitrexed, to determine the dose limiting toxicity and maximum tolerated dose.